Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Baylé FJ. Kasper S, et al. J Clin Psychiatry. 2010 Feb;71(2):109-20. doi: 10.4088/JCP.09m05347blu. J Clin Psychiatry. 2010. PMID: 20193645 Clinical Trial.
Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study.
Stein DJ, Ahokas A, Jarema M, Avedisova AS, Vavrusova L, Chaban O, Gruget C, Olivier V, Picarel-Blanchot F, de Bodinat C. Stein DJ, et al. Eur Neuropsychopharmacol. 2017 May;27(5):526-537. doi: 10.1016/j.euroneuro.2017.02.007. Epub 2017 Mar 12. Eur Neuropsychopharmacol. 2017. PMID: 28298261 Free article. Clinical Trial.
12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.
Stein DJ, Khoo JP, Ahokas A, Jarema M, Van Ameringen M, Vavrusova L, Hӧschl C, Bauer M, Bitter I, Mosolov SN, Olivier V, Matharan S, Picarel-Blanchot F, de Bodinat C. Stein DJ, et al. Among authors: picarel blanchot f. Eur Neuropsychopharmacol. 2018 Aug;28(8):970-979. doi: 10.1016/j.euroneuro.2018.05.006. Epub 2018 Jul 6. Eur Neuropsychopharmacol. 2018. PMID: 30135032 Clinical Trial.
Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
Udristoiu T, Dehelean P, Nuss P, Raba V, Picarel-Blanchot F, de Bodinat C. Udristoiu T, et al. J Affect Disord. 2016 Jul 15;199:6-12. doi: 10.1016/j.jad.2016.03.048. Epub 2016 Mar 26. J Affect Disord. 2016. PMID: 27054610 Clinical Trial.
23 results